LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Kodu・Aktsiate loetelu・Ascendis Pharma A-S ADR

Ascendis Pharma A-S ADR

Suletud

SektorTervishoid

218.15 4.49

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

207.85

Max

228

Põhinäitajad
By Trading Economics
Sissetulek	-22M -61M
Müük	56M 214M
Kasumimarginaal	-28.549
Töötajad	1,017
EBITDA	-56M -53M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+18.24% upside

Turustatistika
By TradingEconomics
Turukapital	785M 13B
Eelmine avamishind	213.66
Eelmine sulgemishind	218.15

Uudiste sentiment

By Acuity

50%

158 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

157.66 / 167.29 Toetus ja vastupanu

Ascendis Pharma A-S ADR Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. dets 2025, 22:53 UTC

Omandamised, ülevõtmised, äriostud

Fortescue to Take Full Control of US$101 Million Copper Miner Alta

13. dets 2025, 00:04 UTC

Omandamised, ülevõtmised, äriostud

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6 Billion, Bloomberg Reports, Citing Sources

14. dets 2025, 23:46 UTC

Market Talk

Gold Edges Higher Amid Some Tailwinds -- Market Talk

14. dets 2025, 23:36 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

14. dets 2025, 22:38 UTC

Omandamised, ülevõtmised, äriostud

Fortescue to Take Full Control of US$101M Copper Miner Alta

14. dets 2025, 22:02 UTC

Omandamised, ülevõtmised, äriostud

Fortescue: Transaction Is Consistent With Critical Minerals Strategy

14. dets 2025, 22:01 UTC

Omandamised, ülevõtmised, äriostud

Fortescue: Alta Owns the Canariaco Project in Northern Peru

14. dets 2025, 22:01 UTC

Omandamised, ülevõtmised, äriostud

Fortescue: Alta Directors Unanimously Recommend Proposal, Will Vote in Favor

14. dets 2025, 22:00 UTC

Omandamised, ülevõtmised, äriostud

Fortescue: Agreement Implies Total Equity Value of C$139 Million

14. dets 2025, 22:00 UTC

Omandamised, ülevõtmised, äriostud

Fortescue to Pay C$1.40/Share for Securities It Does Not Already Own

14. dets 2025, 21:59 UTC

Omandamised, ülevõtmised, äriostud

Fortescue to Acquire Remaining 64% of Alta Copper

14. dets 2025, 17:00 UTC

Tulu

Tonka Trucks Gambled on Keeping Production in China and Survived -- Barely -- WSJ

14. dets 2025, 08:30 UTC

Omandamised, ülevõtmised, äriostud

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

13. dets 2025, 16:48 UTC

Omandamised, ülevõtmised, äriostud

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13. dets 2025, 08:00 UTC

Omandamised, ülevõtmised, äriostud

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13. dets 2025, 07:00 UTC

Omandamised, ülevõtmised, äriostud

A Chubb/AIG Deal Could Be Good for Shareholders and a Coup for Greenberg Family -- Barrons.com

13. dets 2025, 00:24 UTC

Omandamised, ülevõtmised, äriostud

Want a Piece Of SpaceX? -- Barrons.com

12. dets 2025, 23:49 UTC

Omandamised, ülevõtmised, äriostud

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

12. dets 2025, 22:52 UTC

Market Talk

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

12. dets 2025, 22:32 UTC

Tulu

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. dets 2025, 20:45 UTC

Tulu

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

12. dets 2025, 20:41 UTC

Market Talk

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

12. dets 2025, 20:20 UTC

Market Talk

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

12. dets 2025, 19:23 UTC

Tulu

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

12. dets 2025, 18:35 UTC

Omandamised, ülevõtmised, äriostud

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

12. dets 2025, 18:33 UTC

Omandamised, ülevõtmised, äriostud

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

12. dets 2025, 18:31 UTC

Market Talk

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

12. dets 2025, 17:49 UTC

Tulu

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

12. dets 2025, 17:34 UTC

Omandamised, ülevõtmised, äriostud

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

Võrdlus sarnastega

Hinnamuutus

Ascendis Pharma A-S ADR Prognoos

Hinnasiht

By TipRanks

18.24% tõus

12 kuu keskmine prognoos

Keskmine 260.62 USD 18.24%

Kõrge 325 USD

Madal 220 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Ascendis Pharma A-S ADR 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

14 ratings

Osta

Hoia

Müü

Põhineb 14 analüütiku instrumendi Ascendis Pharma A-S ADR aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

157.66 / 167.29Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

158 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.